Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III immunogenicity and safety study of a recombinant trivalent HPV vaccine in healthy Chinese females aged 9-26 years
CTR20212152Phase 3Active
- Sponsor
- Beijing Health Guard
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant trivalent human papillomavirus (types 16/18/58) vaccine in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), cervical carcinoma in situ, Cervical Cancer (CC), vulvar intraepithelial neoplasia (VIN), sponsored by Beijing Health Guard. Started Oct 2021; status: active.
02
Drugs
recombinant trivalent human papillomavirus (types 16/18/58) vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)cervical carcinoma in situCervical Cancer (CC)vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on CTR20212152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212152.